Looks like finally (due to share price drop and potential 'low ball takeover offer'), the Board has finally woken up to the fact that shareholders are extremely disappointed in the management of the FDA approval process and communications with shareholders and the broader markets.
The Board has decided that paid research is needed. See here.
https://static1.squarespace.com/static/5af533a312b13fb602fe7d7b/t/62b4077e5bae901e3630aec7/1655965568159/Cyclopharm+research+update+24+06+2022.pdf
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
-0.010(1.03%) |
Mkt cap ! $106.6M | |||
| Open | High | Low | Value | Volume |
| 97.5¢ | 98.0¢ | 95.5¢ | $78.46K | 81.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 459 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 50945 | 1 |
View Market Depth
| Last trade - 15.59pm 20/06/2025 (20 minute delay) ? |
| CYC (ASX) Chart |